Kimia Biosciences Ltd Stock Price Today (NSE: KIMIABL)
Fundamental Score
Kimia Biosciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kimia Biosciences Ltd share price today is ₹23.55, down 10.89% on NSE/BSE as of 30 March 2026. Kimia Biosciences Ltd (KIMIABL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹137.11 (Cr). The 52-week high for KIMIABL share price is ₹86.85 and the 52-week low is ₹24.00. At a P/E ratio of 16.76x, KIMIABL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 186.78% and a debt-to-equity ratio of 3.11.
Kimia Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Kimia Biosciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Kimia Biosciences Share Price: A Conservative Value Investor's Perspective
The pharmaceutical sector, while possessing inherent defensive qualities due to consistent healthcare demand, is often subject to intense regulatory scrutiny and pricing pressures. This makes a thorough, conservative approach crucial when evaluating individual companies. This analysis focuses on the Kimia Biosciences share price (₹31.780001) from the perspective of a value investor prioritizing capital safety, and forms part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
Currently, Kimia Biosciences trades at a PE ratio of 16.76. While seemingly attractive, it's essential to compare this with sector peers. For instance, assessing the management quality of a company like
Mankind Pharma Ltd and its strategic execution provides valuable context. A detailed comparison against the management quality and operational efficiency displayed by entities like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd helps to gauge Kimia Biosciences' relative positioning within the competitive landscape.A particularly noteworthy metric is Kimia Biosciences' ROCE of 41.8%. This impressive return on capital employed suggests efficient utilization of capital and a strong ability to generate profits from its investments. This high ROCE can contribute to the development of a sustainable economic moat. The ability to consistently generate high returns allows the company to reinvest in research and development, expand its product portfolio, or strengthen its distribution network, creating barriers to entry for competitors.
However, a single metric never paints the whole picture. Further investigation is warranted to understand the sustainability of this ROCE. Factors to consider include the source of these returns (e.g., specific products, geographies), the presence of any significant competitive advantages, and the potential impact of future regulatory changes or competitive pressures. A conservative approach demands a detailed evaluation of the balance sheet strength, cash flow generation, and long-term debt obligations to ascertain the overall financial health and risk profile of Kimia Biosciences.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kimia Biosciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KIMIABL across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (186.78%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (41.80%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 16.76 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (20.65%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (46.61% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (47.21% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (74.94%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Margin Pressure Concerns (3.90%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-36.65%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (2.27% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Elevated Debt Levels (D/E: 3.11)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Limited Institutional Interest (FII+DII: 0.38%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Kimia Biosciences Ltd Financial Statements
Comprehensive financial data for Kimia Biosciences Ltd including income statement, balance sheet and cash flow
About KIMIABL (Kimia Biosciences Ltd)
Kimia Biosciences Ltd is a dynamic pharmaceutical company dedicated to the innovation and production of high-quality Active Pharmaceutical Ingredients (APIs). With a strong foundat...ion in research and development, Kimia Biosciences is committed to addressing the evolving healthcare needs of a global market. The company operates with a focus on delivering reliable and cost-effective solutions to its partners, upholding stringent quality standards throughout its manufacturing processes. Kimia Biosciences strives to be a trusted source for essential pharmaceutical components, contributing to the development of life-enhancing medications and therapies that benefit patients worldwide. Kimia Biosciences Ltd specializes in synthesizing and distributing a diverse range of APIs that serve as the building blocks for various therapeutic treatments. Their extensive product portfolio encompasses APIs targeting prevalent health conditions, including cardiovascular diseases, metabolic disorders, and central nervous system ailments. The company is dedicated to expanding its API offerings to meet the demands of an ever-changing healthcare landscape. By focusing on both established and emerging therapeutic areas, Kimia Biosciences aims to provide comprehensive API solutions that empower pharmaceutical companies to formulate innovative and accessible medications. At the heart of Kimia Biosciences Ltd lies a steadfast commitment to quality and compliance. Their state-of-the-art manufacturing facilities adhere to the highest industry standards and are equipped with advanced technologies to ensure the consistent production of superior APIs. The company implements rigorous quality control measures at every stage of the manufacturing process, from sourcing raw materials to final product testing and packaging. Kimia Biosciences is dedicated to maintaining full transparency and traceability, providing customers with the assurance of safe, effective, and reliable APIs that meet global regulatory requirements.
Company Details
Key Leadership
KIMIABL Share Price: Frequently Asked Questions
What is the current share price of Kimia Biosciences Ltd (KIMIABL)?
As of 30 Mar 2026, 12:07 pm IST, Kimia Biosciences Ltd share price is ₹23.55. The KIMIABL stock has a market capitalisation of ₹137.11 (Cr) on NSE/BSE.
Is KIMIABL share price Overvalued or Undervalued?
KIMIABL share price is currently trading at a P/E ratio of 16.76x, compared to the industry average of 31.77x. Based on this relative valuation, the Kimia Biosciences Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of KIMIABL share price?
The 52-week high of KIMIABL share price is ₹86.85 and the 52-week low is ₹24.00. These values are updated daily from NSE/BSE price data.
What factors affect the Kimia Biosciences Ltd share price?
Key factors influencing KIMIABL share price include quarterly earnings growth (Sales Growth: 20.65%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Kimia Biosciences Ltd a good stock for long-term investment?
Kimia Biosciences Ltd shows a 5-year Profit Growth of 47.21% and an ROE of 186.78%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 3.11 before investing in KIMIABL shares.
How does Kimia Biosciences Ltd compare with its industry peers?
Kimia Biosciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare KIMIABL share price P/E of 16.76x and ROE of 186.78% against the industry averages to determine competitive standing.
What is the P/E ratio of KIMIABL and what does it mean?
KIMIABL share price has a P/E ratio of 16.76x compared to the industry average of 31.77x. Investors pay ₹17 for every ₹1 of annual earnings.
How is KIMIABL performing according to Bull Run's analysis?
KIMIABL has a Bull Run fundamental score of 52.6/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does KIMIABL belong to?
KIMIABL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Kimia Biosciences Ltd share price.
What is Return on Equity (ROE) and why is it important for KIMIABL?
KIMIABL has an ROE of 186.78%, which indicates excellent management efficiency. ROE measures how efficiently Kimia Biosciences Ltd generates profits from shareholders capital.
How is KIMIABL debt-to-equity ratio and what does it indicate?
KIMIABL has a debt-to-equity ratio of 3.11, which indicates high leverage that increases financial risk.
What is KIMIABL dividend yield and is it a good dividend stock?
KIMIABL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Kimia Biosciences Ltd shares.
How has KIMIABL share price grown over the past 5 years?
KIMIABL has achieved 5-year growth rates of: Sales Growth 2.27%, Profit Growth 47.21%, and EPS Growth 46.61%.
What is the promoter holding in KIMIABL and why does it matter?
Promoters hold 74.94% of KIMIABL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Kimia Biosciences Ltd.
What is KIMIABL market capitalisation category?
KIMIABL has a market capitalisation of ₹137 crores, placing it in the Small-cap category.
How volatile is KIMIABL stock?
KIMIABL has a beta of N/A. A beta > 1 suggests the Kimia Biosciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is KIMIABL operating profit margin trend?
KIMIABL has a 5-year average Operating Profit Margin (OPM) of 3.90%, indicating the company's operational efficiency.
How is KIMIABL quarterly performance?
Recent quarterly performance shows Kimia Biosciences Ltd YoY Sales Growth of 20.65% and YoY Profit Growth of -36.65%.
What is the institutional holding pattern in KIMIABL?
KIMIABL has FII holding of 0.00% and DII holding of 0.38%. Significant institutional holding often suggests professional confidence in the Kimia Biosciences Ltd stock.